OSI-420 - CAS 183320-51-6
Catalog number: B0084-286627
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
OSI-420 (CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for the inhibition of human EGFR and EGFR autophosphorylation in tumor cells.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-286627 10 mg $198 In stock
B0084-286627 50 mg $598 In stock
Bulk Inquiry
OSI420; OSI-420; OSI 420; CP473420; CP-473420; CP 473420; Desmethyl Erlotinib.
For research used only
Canonical SMILES:
1.A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.
Svedberg A1, Gréen H2, Vikström A3, Lundeberg J4, Vikingsson S5. J Pharm Biomed Anal. 2015 Mar 25;107:186-95. doi: 10.1016/j.jpba.2014.12.022. Epub 2014 Dec 25.
A liquid chromatography tandem mass spectrometry method was developed and validated for quantification of erlotinib and its metabolites in human plasma. The method is suitable for therapeutic drug monitoring and pharmacokinetic studies. The substances were extracted using protein precipitation, separated on a BEH XBridge C18 column (100 ×2.1 mm, 1.7 μm) by gradient elution at 0.7 mL/min of acetonitrile and 5 mM ammonium acetate. The concentration was determined using a Waters Xevo triple quadrupole mass spectrometer in a multi reaction monitoring mode. The total run time was 7 min. Deuterated erlotinib and OSI-597 were used as internal standard for erlotinib and its metabolites, respectively. Erlotinib, OSI-420 and didesmethyl erlotinib were quantified in the concentration range 25-5000 ng/mL, 0.5-500 ng/mL and 0.15-10 ng/mL, respectively. Precision and accuracy was <14% except for OSI-420 at LLOQ (17%). Extraction recovery was above 89%, 99% and 89% for erlotinib, OSI-420 and didesmethyl erlotinib, respectively.
2.A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.
Macpherson IR1, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR. Eur J Cancer. 2013 Mar;49(4):782-9. doi: 10.1016/j.ejca.2012.09.036. Epub 2012 Oct 22.
AIM: To determine the maximum tolerated dose (MTD) of OSI-930 that can be combined with erlotinib, and establish recommended phase 2 doses when both agents are administered daily in patients with advanced solid tumours.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products

CAS 781613-23-8 XL-647

(CAS: 781613-23-8)

XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...

CAS 1213269-23-8 WZ-4002

(CAS: 1213269-23-8)

WZ-4002 is an EGFR phosphorylation inhibitor with selectivity for EGFR T790M. It has a framework of pyrimidine compound which is different from other EGFR inhib...

CAS 873837-23-1 BMS-599626 Hydrochloride

BMS-599626 Hydrochloride
(CAS: 873837-23-1)

BMS-599626 Hydrochloride is a selective and efficacious orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases with potential antineoplastic ...

CAS 1375465-09-0 CNX-2006

(CAS: 1375465-09-0)

CNX-2006 is a potent and mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbourin...

CAS 1214265-57-2 WZ-8040

(CAS: 1214265-57-2)

WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor with potential anticancer activity. WZ8040 is about 30-fold more potent against EGFR T790M, ...

CAS 1214265-56-1 WZ-3146

(CAS: 1214265-56-1)

WZ-3146 is an irreversiblely inhibitor against EGFR T790M with potential anticancer activity.

CAS 136831-48-6 RG13022

(CAS: 136831-48-6)

RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.

(CAS: 180288-69-1)

Trastuzumab is a monoclonal antibody drug for the treatment of breast cancer which is HER2 receptor positive. It acts via binding to HER2 receptor to suppress c...

Chemical Structure

CAS 183320-51-6 OSI-420

Quick Inquiry

Verification code

Featured Items